 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Alnylam RSV Drug Fails in Phase IIb; Company to Weigh Options with Regulators
May 31, 2012
Alnylam RSV Drug Fails in Phase IIb; Company to Weigh Options with Regulators
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Unveiling New Strategy, Alnylam Aims to Debut Five Clinical Candidates by 2015
January 6, 2011 / Gene Silencing News - Alnylam May Not Reach Partnership Goal for ‘09, Partner Cubist to Focus on Follow-On RSV Rx
November 12, 2009 / Gene Silencing News - For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News - Alnylam, Cubist Say 90-Day Data Shows RSV Drug to Be Safe, Suggests Efficacy
July 23, 2009 / Gene Silencing News - Alnylam Adds New Program to Pipeline as It Shelves Anemia Candidate
January 10, 2013 / Gene Silencing News